H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $22 from $20 and keeps a Buy rating on the shares. The firm cites the addition of tradipitant sales into the model following the approval for the treatment of motion sickness for the target boost.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Midday Fly By: Nvidia said to see strong H200 demand in China
- Morning Movers: Nvidia up as report points to strong demand in China
- Video: Nvidia responding to strong demand for H200 in China
- Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley
- Vanda motion sickness approval comes with ‘broad’ label, says Cantor